1 not yet recruiting, 1 withdrawn. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Not yet recruiting 1, Withdrawn 1 |
Follow MASLD: new trials by email Literature Review of MASLD trials Research Report on MASLD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 1500 | 2026-11-06 | 2026-10-02 |
| A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH denifanstat, Placebo - MASLD, MASH | Phase 3 | Withdrawn | Sagimet Biosciences Inc. | 2025-03-01 | 2025-05-15 |
Fatty Liver (2) · Non-alcoholic Fatty Liver Disease (2) · Insulin Resistance (1) · Liver Cirrhosis (1) · Obesity (1)
Digestive System Diseases (2) · Liver Diseases (2) · Body Weight (1) · Fibrosis (1) · Glucose Metabolism Disorders (1) · Hyperinsulinism (1) · Metabolic Diseases (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1) · Overnutrition (1) · Overweight (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
TVB-2640 (1)
Regeneron Pharmaceuticals (1) · Sagimet Biosciences Inc. (1)